MedPath

zinc sulfate supplementation in Glioblastoma multiform

Phase 2
Conditions
Glioblastoma multiform.
Malignant neoplasm of brain
Registration Number
IRCT20190430043432N1
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
27
Inclusion Criteria

New diagnosed patients with glioblastoma multi form
Normal function of liver, kidneys and hematologic system
Normal zinc and cupper serum levels

Exclusion Criteria

Pregnancy
History of another malignancy
History of allergy to zinc sulfate supplementation

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ifetime from diagnosis to death. Timepoint: Every 3 months to at least 12 months. Method of measurement: Visit the patients and find out if they are alive (Survival Calculation by Week).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath